Committees:
- Human Resources and Compensation
- Nominating and Governance
- Value Creation
Attributes and Skills Provided to the Board:
- Executive leadership experience at healthcare and life sciences companies
- Investment stewardship experience
- Public-company director and executive experience
- Global business experience
- Mergers & acquisitions/integrations
- Growth strategies and market expansion
- Experience in highly regulated industries
Expertise Provided to the Board:
Dr. Martin D. Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. An experienced public-company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, he brings valuable operational insight and industry expertise to the Azenta Board. Dr. Madaus has a proven track record of creating shareholder value in both public and private life science companies. He has notable experience in strategy, mergers and acquisitions and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG).